psychedelics investing Compass Pathways Announces Six-Month Data from Second Phase 3 Trial Confirming Rapid and Durable Profile
psychedelics investing Optimi Health Completes Psilocybin Export to Australia for Patients With Treatment-Resistant Depression
psychedelics investing A Breakthrough-Designated Depression Drug Is 86% Through Its Phase 3, With Topline Data Due This Year
psychedelics investing Optimi Health Completes First Export of Psilocybin to the United Kingdom for Phase 2 Clinical Trial
psychedelics investing Optimi Health Secures Ibogaine Supply and Commences Finished Drug Product Development
psychedelics investing Optimi Health Secures Ibogaine Supply and Commences Finished Drug Product Development
psychedelics investing Optimi Health Completes Commercial Psilocybin Production to Address Treatment-Resistant Depression in Australia
psychedelics investing Optimi Health Welcomes Expanded Psychedelic-Assisted Therapy Access Under Updated Authorized Prescriber Framework in Australia
psychedelics investing Compass Pathways to Participate in Jefferies Global Healthcare Conference on June 3, 2026
psychedelics investing Optimi Health Announces Closing of Oversubscribed US$15 Million Public Offering
psychedelics investing Optimi Health Announces Pricing of Oversubscribed US$15 Million Public Offering and Nasdaq Uplisting
psychedelics investing Compass Pathways to Participate in RBC Capital Markets Global Healthcare Conference on May 19-20, 2026
psychedelics investing Compass Pathways Announces First Quarter 2026 Financial Results and Business Highlights
Precipitate Gold Strengthens Board with Appointment of Dominican Business Leader Pelayo Troncoso and Mining Finance Executive John Wenger
America Needs Antimony, and This Nevada Explorer Just Defined One of the Largest Domestic Resources of It
